Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Cybin

Recent news which mentions Cybin

Cybin: Positive Data Announced From Innovative Drug Trial
Tags General Cybin Benzinga
From Benzinga
Cybin: Psychedelic Based BioPharma Company To Announce Much Anticipated Updates For Its Ongoing Clinical Trials
Tags Cybin Interview Benzinga
From Benzinga
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Tickers CYBN DMT
Tags Psychedelics Benzinga CYBN
From Benzinga
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Tickers CYBN MSSTF
Tags MSSTF Cybin News
From Benzinga
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
Tickers CYBN DEA MDD
Tags CYBN MDD Legal
From Benzinga
This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares
Tickers CYBN SEC
Tags Psychedelics Benzinga CYBN
From Benzinga
How Does Ketamine Affect The Brain Over Time?
Tags Psychedelics Benzinga contributors
From Benzinga
Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference
Tickers CYBN
Tags Psychedelics Benzinga Penny Stocks
From Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
Tickers CYBN
Tags Benzinga Psychedelics Biotech
From Benzinga
Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics
Tickers CYBN
Tags CYBN Markets Market News
From Benzinga
WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies
Tickers CYBN
Tags Cannabis Market News Markets
From Benzinga
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
Tickers AGN CYBN PTX
Tags Cannabis PTX Market News
From Benzinga
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain
Tickers CYBN
Tags CYBN Kernel Benzinga
From Benzinga
Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder
Tickers CYBN
Tags CYBN Markets Market News
From Benzinga
Five Companies Developing Second Generation Psychedelics For Mental Health
Tickers CYBN ENVB FTRP MNMD
Tags MNMD Benzinga Psychedelics
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
Tickers CYBN
Tags Doug Drysdale Market News CYBN
From Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
Tickers CYBN
Tags Cannabis Market News Markets
From Benzinga
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
Tickers CYBN
Tags Markets Bryan Johnson Market News
From Benzinga
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) Files Two International Patent Applications In Support Of The Company's Research Phase Programs
Tickers CYBN
Tags CYBN Partner Content General
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS